# A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD

> **NCT04331730** · PHASE2 · COMPLETED · sponsor: **Alkahest, Inc.** · enrollment: 107 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** AKST4290
- **DRUG:** Placebo
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT04331730
- **Lead sponsor:** Alkahest, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-28
- **Primary completion:** 2021-08-19
- **Final completion:** 2021-09-16
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2022-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04331730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04331730, "A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04331730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*